GlobeNewswire

Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US

Share

Bagsværd, Denmark, 4June 2021 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy™ (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management. Wegovy™ is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity (initial BMI≥30 kg/m2) or overweight (initial BMI≥27 kg/m2) with at least one weight-related comorbidity.

Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist   therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase 3a clinical trial programme. Across the trials in people without type 2 diabetes, an average weight loss of 17-18%1 sustained over 68 weeks was reported for people with obesity treated with Wegovy™. Wegovy™ demonstrated a safe and well-tolerated profile across the programme, with the most common adverse events being gastrointestinal.

“The approval of Wegovy™ in the US brings great promise to people with obesity. Despite the best efforts to lose weight, many people with obesity struggle to achieve and maintain weight loss due to physiological responses that favour weight regain,” said Martin Holst Lange, executive vice president, Development at Novo Nordisk. “The unprecedented weight loss for an anti-obesity medication marks a new era in the treatment of obesity, and we now look forward to making Wegovy™ available to people living with obesity in the US”.

Novo Nordisk expects to launch WegovyTM in the United States later in June 2021.

Conference call
On 7 June at 8.30 CEST, corresponding to 2.30 am EDT, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com.

About obesity
Obesity is a chronic disease that requires long-term management. It is associated with many serious health complications and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, heart disease, obstructive sleep apnoea, non-alcoholic fatty liver disease and certain types of cancer. The current COVID-19 pandemic has highlighted that obesity also increases the risk for severe illness and hospitalisation due to COVID-19.

The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. Approximately 650 million adults are estimated to live with obesity worldwide.

About Wegovy™ (semaglutide 2.4 mg) and STEP
Semaglutide 2.4 mg is a GLP-1 receptor agonist, with 94% similarity to naturally occurring human GLP-1 hormone. It induces weight loss by reducing hunger, increasing feeling of fullness and thereby helping people eat less and reduce their calorie intake. Once-weekly semaglutide 2.4 mg injection is approved for the treatment of adults with obesity or overweight in the US, in addition to diet and exercise.

Semaglutide 2.4 mg for weight management is currently under regulatory review in the EU and other countries. The submissions are based on the results from the STEP (Semaglutide Treatment Effect in People with obesity) phase 3 clinical development programme. The global clinical phase 3a programme consists of four trials and enrolled approximately 4,500 adults with overweight or obesity.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:
Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com
Michael Bachner (US)+1 609 664 7308mzyb@novonordisk.com
Investors:
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com

Company announcement No 38 / 2021


1 Based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies. When using a treatment policy estimand, 15-17% weight loss was reported.


Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Data analysis from dLab to boost the digitalization for Karlskoga Energi & Miljö24.6.2021 09:55:00 CEST | Press release

Regional utilities company Karlskoga Energi & Miljö AB has been using the smart data analytics solution from cleantech company Dlaboratory Sweden AB (publ) since 2020. A useful solution for avoiding power outages and identifying faults, dLab’s system is the starting point for the energy company’s digitalization journey. Energy company Karlskoga Energi & Miljö with its subsidiary Karlskoga Elnät has around 15 000 customers along a 1 700 km grid in the middle of the beautiful region of Värmland. Digitalization is a high priority throughout the organization, whether it means providing fiber optics for consumers, or the dInsight Analytics Platform from dLab. -The solution from dLab pushes us to work in a completely new way; from monitoring and analysis to becoming proactive, using data to prevent, rather than fix a problem. This requires new knowledge in the organization, but also a new way of working, says Jimmy Lundberg, Head of Distribution at Karlskoga Elnät. The company chose dLab’s s

Nokia launches next-generation AirScale 5G portfolio powered by ReefShark technology24.6.2021 09:00:00 CEST | Press release

Press Release Nokia launches next-generation AirScale 5G portfolio powered by ReefShark technology Nokia’s new, industry-leading 5G portfolio covers baseband, radio, and massive MIMO antennas offering huge 5G capacity, coverage, and easy deploymentIntroduces industry’s lightest massive MIMO units at 17kg enabling simplified deployments and faster time to marketNokia’s new comprehensive range of products are powered by Nokia’s latest generation of ReefShark chipsets Nokia’s extended Single RAN accelerates 5G rollouts and cuts overall RAN Total Cost of Ownership 24 June 2021 Espoo, Finland – Nokia today announced the global launch of its latest range of industry-leading AirScale 5G products covering baseband, remote radio heads, and massive MIMO active antennas with digital beamforming. The innovative solutions are powered by the latest generation of Nokia’s ReefShark System-on-Chip (SoC) chipsets and deliver the highest capacity and network performance while enabling efficient deploymen

Huvepharma Announces the Indicative Price Range, Publication of the Prospectus and Start of the Offer Period of Planned IPO24.6.2021 08:15:39 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. This announcement is an advertisement for the purposes of the Prospectus Regulation EU 2017/1129 and underlying legislation, relating to the launch of the Offer (as defined below) by the Company and the proposed Admission (as defined below). This announcement does not constitute a prospectus. This announcement is for information purposes only and is not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy Shares (as defined below) in any jurisdiction, including the United States, Canada, Australia or Japan. Further details about the Offer and the Admission is included in the Prospectus (as defined below). The Prospectus has today been approved by the Netherlands Authority for the Financial Markets (Stich

FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)24.6.2021 07:00:00 CEST | Press release

If approved, PDS would be the first and only eye implant with continuous drug delivery that offers people living with nAMD an alternative to frequent eye injectionsA pivotal study showed PDS extends time between treatments up to six months for more than 98% of patients and provides vision outcomes equivalent to monthly ranibizumab injectionsThe European Medicines Agency has also validated the PDS Marketing Authorisation Application in nAMD Basel, 24 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD). Neovascular AMD is a leading cause of blindness for people aged 60 and over and impacts approximately 20 million people worldwide.1,2,3 If approved, PDS would be a first-of-its-kind therapeutic approach, offering pe

ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting24.6.2021 07:00:00 CEST | Press release

- Data from Phase 3 study ofYselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation; Top-line data from pilot study of Yselty for the treatment of severe adenomyosis to be presented in an ePoster- -Data from IMPLANT1 Phase 2 study of nolasiban for uterine contractility of IVF patients prior to embryo transfer to be presented in an ePoster - GENEVA, Switzerland and BOSTON– June 24, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of data from two of its clinical development programs at the European Society of Human Reproduction and Embryology (ESHRE) Virtual 37th Annual Meeting, being held June 26 - July 1, 2021. Details of the presentations for the Yseltyprogram are as follows: Title: Long-Term Secondary Efficacy of Linzagolix for Heavy Menstrual Bleeding (HMB) Due to Uterine Fibroids (UF): 52-Week Res

Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group24.6.2021 07:00:00 CEST | Press release

Acquires all royalty rights to Maxigesic® IV Assumes sole responsibility for HY-075 and HY-038 – future profit split lapses Gains higher net profit margin for Fusidic Acid Cream in Canada Hyloris CEO and CBDO to resign from the Board of Directors of Alter Pharma Liège, Belgium – 24June 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today announces that it has successfully renegotiated and unwound its earlier license agreements with the Alter Pharma Group. Hyloris will pay the Alter Pharma Group a total lump sum of €5.25 million plus €0.5 million potential earn-out, thereby waiving any further future financial obligations towards the Alter Pharma Group. Hyloris Pharmaceuticals and the Alter Pharma Group have amended and unwound the earlier license agreements as follows: The patent and knowhow license agreement in relation to Maxigesic IV has b

Enento Group makes a strategic investment to add a unique Sales Intelligence service offering by acquiring a part of Goava Sales Intelligence AB with possibility to take majority24.6.2021 07:00:00 CEST | Press release

ENENTO GROUP PLC, STOCK EXCHANGE RELEASE ON 24 JUNE 2021 AT 8.00 A.M. EEST Enento Groupmakes a strategic investment to add a uniqueSales Intelligence service offering byacquiring apart of Goava Sales Intelligence AB with possibility to take majority Enento Group Plc has signed an agreement to acquire part of and become the largest shareholder of the Swedish sales intelligence services company Goava Sales Intelligence AB by subscribing to new preference shares in the company. Within the agreement, Enento in the first stage on 24 June 2021 acquires a 38,3 % (35,1 % fully diluted) shareholding in the company, and at the same time agrees to complete subsequent preference share subscriptions provided that the company fulfills certain preconditions laid out in the business plan, as well as acquires a purchase option to acquire all outstanding shares in the company after a mutually agreed business plan period ending in year 2024 and aiming at gaining a significant market position for the serv